RAC1-Targeting Compound for Neurodegenerative Disease Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, such as Alzheimer's, are unable to halt the progression of the disease and primarily focus on symptom alleviation, with limited success in reducing the toxicity of β-amyloid protein after symptoms appear.
Innovation Solution
A compound is developed that targets the RAC1 network to enhance long-term potentiation and is used in pharmaceutical compositions to prevent and treat neurodegenerative diseases, including Alzheimer's, by regulating RAC1 to strengthen brain learning and memory capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current treatments (cholinesterase inhibitors and NMDA receptor antagonists) are used, then symptoms can be temporarily alleviated, but the disease progression cannot be halted
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (RAC1 network) that drives disease progression, separating the treatment approach from general symptom management. By focusing on RAC1 inhibition, the treatment addresses the root cause rather than just symptoms, enabling disease progression halting while maintaining symptom relief capabilities
Solution Approach 2:
The patent changes the therapeutic parameter from symptomatic relief (current treatments) to disease-modifying action (RAC1 inhibition). This parameter change enables the treatment to both alleviate symptoms and halt progression by targeting the underlying pathological mechanism of RAC1-mediated neurodegeneration
2Object-affected harmful factors
If vaccines targeting Abeta protein are developed after symptoms appear, then an attempt is made to reduce toxicity, but the treatment is too late to be effective
Solution Approach 1:
The patent enables preliminary action by targeting RAC1 inhibition before irreversible neurodegeneration occurs. The RAC1 network is involved in early pathological processes including amyloid processing and neuroinflammation, so inhibiting RAC1 can prevent disease progression and reduce beta-amyloid toxicity before significant neuronal damage occurs, making early intervention effective
Solution Approach 2:
The patent introduces RAC1 inhibition as an intermediary mechanism that connects and addresses multiple pathological features simultaneously. RAC1 acts as a mediator in amyloid processing, neuroinflammation, and synaptic dysfunction, so targeting it provides a unified approach to reduce beta-amyloid toxicity and prevent neurodegeneration at multiple levels
3Reliability
If RAC1 is regulated to enhance long-term potentiation, then brain learning and memory capabilities are strengthened, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts the specific molecular target (RAC1) that controls multiple pathological processes. By focusing on this single key regulator, the treatment simplifies the approach to enhancing learning and memory capabilities while addressing the underlying neurodegeneration, rather than requiring complex multi-target interventions
Solution Approach 2:
The patent exploits the multi-functionality of RAC1, which is involved in amyloid processing, neuroinflammation, and synaptic plasticity. A single RAC1 inhibition strategy simultaneously addresses multiple pathological features and enhances learning/memory through LTP, providing a universal treatment approach that simplifies the overall mechanism while achieving multiple therapeutic goals
Data Source
AI summary
The present invention relates to a compound for preventing and/or treating a neurodegenerative disease. Specifically, the compound of the present invention has a structure as shown in formula I, wherein the definitions of groups and substituents in the formula are as described in the description. Also disclosed are a preparation method for the compound and a use of the compound in preventing and/or treating a neurodegenerative disease.